Inovio spinout Geneos goes independent with a $10.5 million first-round financing for R&D in neoantigen-targeting cancer immunotherapies.
The data show smoking reductions occurred within two days of treatment, sending the nanocap’s stock up as much as 90% in premarket trading.
What if we could prevent opioid addiction before it starts? Reducing exposure to opioids after surgery through better non-opioid pain management options can…
The wipeout prompted Opiant to stop development of OPNT001 in the indication and double down on the rest of its pipeline.
The announcement comes nearly three months after Mereo and OncoMed unveiled their reverse merger.
Enzyvant finds new CEO in former Alexion exec; Arix reappoints CEO after 5-month hunt; and MorphoSys CEO Moroney announces retirement.
Rutgers University scientists have made a surprising discovery that could lead to improved methods for diagnosing and treating human genetic diseases.
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.
Life science VC MPM Capital is looking to boost funding for a select series of early-stage biotechs with a new $400 million fund.
J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.